Skip to main content

Table 1 Main characteristics of HIV-infected patients enrolled in the study

From: Computer-Based Design of an HLA-Haplotype and HIV-Clade Independent Cytotoxic T-Lymphocyte (CTL) Assay for Monitoring HIV-Specific Immunity

      At Enrollment 1 Month After HAART Interruption
Patient Sex Age Race HAART CD4 (N/ µ l) CD8 (N/ µ l) Viral Load (copies/ml) Anti-GAG Peptides CTL (N precursors/ml) CD4 (N/ µ l) CD8 (N/ µ l) Viral Load (copies/ml) Anti-GAG Peptides CTL (N precursors/ml)
C01 F 37 Caucasian Yes 878 1153 <50 922 644 1342 2900 805
C03 F 36 Caucasian Yes 795 559 <50 727 678 1724 170000 7068
C04 M 47 Caucasian Yes 788 1508 <50 452 347 2597 670000 2619
C05 F 26 Caucasian Yes 759 1427 <50 3710 894 1995 300 7182
C08 F 50 Caucasian Yes 501 1446 <50 864 340 2726 71000 6815
C10 F 40 Caucasian Yes 502 651 <50 391 509 956 80 383
C11 F 38 Caucasian Yes 512 435 <50 391 401 1505 85000 4214
C13 F 31 Caucasian Yes 625 623 <50 141 493 705 42000 187
C15 F 30 Caucasian Yes 622 870 <50 87 426 1683 10000 505
C16 F 34 Caucasian Yes 601 948 <50 15831 471 701 19000 2804
C18 M 55 Caucasian Yes 632 1392 <50 417 522 1508 57000 151
C29 M 47 Caucasian Yes 862 1425 <50 1567 382 1444 770 2021
A66 F 35 African Naive 1132 907 11027 1451 n.a.* n.a. n.a. n.a.
A67 M 36 African Naive 511 1142 11230 1028 n.a. n.a. n.a. n.a.
A68 F 34 African Yes 535 2153 6162 3229 n.a. n.a. n.a. n.a.
A69 F 33 African Naive 186 1458 473480 728 n.a. n.a. n.a. n.a.
A70 M 42 African Naive 174 1258 149548 1887 n.a. n.a. n.a. n.a.
  1. *n.a., not applicable.